Immunotherapy Special Issue 2021

Patients with cancer who are treated with checkpoint inhibitors or immunotherapy, along with other treatments, run the risk of developing ILD as a side effect.

Thanks to ongoing research and clinical trials, it seems that there are always new immunotherapies emerging.

On behalf of the Head and Neck Cancer Alliance, Dr. Michael Moore spoke with CURE® about emerging therapies that potentially offer exciting new options for the future.

One expert tells patients to ‘hang tight’ as immunotherapy options are getting better each year.

Even with newer technologies such as mRNA, experts predict it will be a few years before another cancer vaccine is approved.

BiTE therapy could lead to better ways to target the immune system, while minimizing the chance of resistance.

First immunotherapy, intralesional therapy, is making a comeback and producing durable remissions for a subgroup of patients with cancer.

Experts urge patients to stop playing the wait-and-see game: There’s no ‘playbook’ for immunotherapy-related toxicities, and side effects can be managed if caught early.

To avoid the financial burden of costly therapies, patients with cancer receiving immunotherapy treatments should talk with their health care team and not settle for no as an answer from their health insurance provider, according to an expert.